Illumina’s goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for them to deliver innovative, flexible, and scalable solutions to meet the needs of their customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, they strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
Zymo Research is a privately-owned company that has been proudly serving the scientific community with state-of-the-art molecular biology tools since 1994. “The Beauty of Science is to Make Things Simple” is a mantra that is reflected in every Zymo Research product from epigenetics to DNA/RNA purification technologies. Historically recognized as the leaders in Epigenetics, today Zymo Research is breaking boundaries with innovative solutions for Microbiome measurements. Zymo Research is the first company to develop microbiomics solutions from collection to conclusion based on new rigorous standards for Microbiome measurements. Zymo Research has been leading the initiative to improve reproducibility and accuracy in the field by developing the first commercially available microbiome (mock microbial community) standards.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
With a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings. Originally, founded in 1978 in Madison, Wisconsin, USA, Promega has branches in 16 countries and more than 50 global distributors serving 100 countries. If you are looking for your local Promega sales office, manufacturing facility or product distributor, you can find contact information here. A cornerstone of Promega business practice is supporting customers, community and employees. Promega holds significant intellectual property rights and licenses in several key areas that form a foundation for its diverse portfolio including: Bioluminescence, including engineered luciferases, luciferase reporter vectors and luciferase substrates, Short tandem repeat (STR) detection for STR-based cell line authentication, human identification, cell and tissue characterization, and mixed sample detection HaloTag® protein labeling and capture technology.
CosmosID is a bioinformatics company focused on rapid identification of microorganisms for infectious disease diagnostics, public health surveillance, food safety inspections, pharmaceutical discovery, and microbiome analysis for health and wellness. From a post-sequencing metagenomic sample we identify bacteria, DNA viruses, fungi, parasites, antibiotic resistance and virulence genes, and more within minutes. With the use of our curated genome databases and both sensitivity and specificity >95% we are unmatched in our ability to detect microorganisms in metagenomic samples. The speed and universal nature of the test, and the ability to detect both pathogens and antimicrobial resistance genes at once will improve patient outcomes, shortening the length of hospitalization and avoiding complex therapies to significantly reduce total cost of care.
The mission of GIS Cloud is not only to supplement desktop solutions, but extend and enrich their capabilities through the potential the Internet provides. It is a more accessible way of visualizing, analyzing and sharing geospatial data, provided as software as a service, but also available free of charge. Emphasis is on collaboration between colleagues or fellow GIS Cloud users, easy access to data regardless of user’s location and giving a chance to quickly and easily publish maps on the web, share anywhere in the world or use GIS platform to build geo and location aware apps.